Traditionally, drug-induced changes in cytochrome P450 isoenzyme activity, causing
changes in drug metabolism and bioavailability, have been the main focus of drug …

The purpose of this study is to develop a kinetic model that can predict the in vivo absorption
of P‐glycoprotein (P‐gp) substrates from in vitro data. Apical (AP) to basal (BL) absorptive …

Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one
active metabolite, and seven non-CNS-active compounds were tested in three P …

P-glycoprotein (P-gp) is a crucial membrane transporter situated on the cell's apical surface,
being responsible for eliminating xenobiotics and endobiotics. P-gp modulators are …

Abstract P-glycoprotein (P-gp) is a member of ATP-binding cassette (ABC) superfamily
which extrudes chemotherapeutic agents out of the cell. Suppression of this efflux activity …

Background P-glycoprotein (P-gp) is a multidrug efflux transporter that has a defined role in
the absorption and disposition of drugs. Many studies have investigated the potential …

Abstract P-glycoprotein (Pgp), also called MDR1, the product of the multidrug resistance
(MDR) gene, is an ATP-dependent efflux transporter that affects the absorption, distribution …

Background: Edoxaban, an oral direct factor Xa inhibitor, is in phase 3 clinical development
for stroke prevention in AF and treatment of VTE. P-gp, an efflux transporter, can prevent the …

In vitro inhibition of P-glycoprotein (P-gp) expressed in cells is routinely used to predict the
potential of in vivo P-gp drug interactions at the human blood-brain barrier (BBB). The …

Digoxin, which has a very narrow therapeutic window, is one of the most commonly
prescribed drugs in the treatment of congestive heart failure. In some cases of atrial …